Overactive Bladder Associated With HTLV-1 Clinical Trial
Official title:
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
It's a double blind, placebo controlled study to assess the efficacy of Propantheline
Bromide to treat overactive bladder (OAB) in HTLV 1 infected patients.
We think that the treatment of the OAB with Propantheline could reduce nocturia and
frequency in sixty percent.
Double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to
treat overactive bladder (OAB) in HTLV 1 infected patients
Treatment Group Propantheline Bromide: 15mg, three times daily for 08 weeks.
Control Group Placebo 03 times daily
Case definition Clinically defined OAB patients (ICS criteria), infected by HTLV-1.
Frequency was defined as more than 08 daytime voids. Nocturia was defined as more than 02
voids after sleeping.
Inclusion criteria More than 18 year. HTLV-1 infected patients with overactive bladder.
Negative culture of urine. Without neurological impairment.
Exclusion criteria Persistently positive urine culture
History of:
Allergy to medication, head or spinal trauma. Head and neck, neurological,spinal, lower
abdominal or pelvic surgery. Stroke. Users of urinary catheters.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment